Previous close | 1,390.34 |
Open | 1,390.34 |
Bid | 0.00 x 4700 |
Ask | 1,435.00 x 200 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 12 |
Market cap | 1.873T |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 26.67 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 45.42 (3.27%) |
Ex-dividend date | 21 Mar 2024 |
1y target est | N/A |
Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards.
Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, looking exclusively at women. The findings showed the Evolut self-expanding valve (SEV) was associated with significantly less bioprosthetic valve dysfunction (BVD) and improved quality of life for women with symptomatic severe aortic stenosis (A
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD) mapping catheter for the treatment of persistent atrial fibrillation (AFib). The SPHERE Per-AF study, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial, c